Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results.

Annals of Oncology · 1 Nov 2026 · Editorial

Arecco, Lambertini

The abstract is read at the publisher; the summary is JClub's.

There's no AI summary of this paper here yet.

Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.

PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer.
New England Journal of Medicine · 5 Nov 2026 · Letter
Read it in JClub
- 1 opens in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42981581
Open in JClub
PARP1 revisited - integrating DNA repair, replication and therapeutics.
Nature Reviews Molecular Cell Biology · 11 Nov 2026 · Review
AI summary · may contain errors
PARP1 recognizes diverse DNA and chromatin structures—such as unligated Okazaki fragments, reversed forks, G-quadruplexes, and R-loops—by interpreting lesion geometry, topology, and chromatin context.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/43015367
Open in JClub

Journals this month

All journals →

Topics moving, week to 13 Nov 2026

All topics →

By field

All journals by field →

Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results.

Related in JClub

PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer.

PARP1 revisited - integrating DNA repair, replication and therapeutics.

Browse JClub